{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:41:51Z","timestamp":1794199311219,"version":"4.8.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7232272"],"award-info":[{"award-number":["7232272"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cirrhotic portal hypertension, the most prevalent and clinically significant complication of liver cirrhosis, manifests as elevated portal venous pressure and is associated with severe complications. Although much research on the mechanisms of portal hypertension has focused on liver fibrosis, less attention has been given to the role of intrahepatic and extrahepatic vascular dysfunction, particularly with respect to extrahepatic vasculature. While the role of hepatic fibrosis in cirrhotic portal hypertension is undeniable, the underlying mechanisms involving intrahepatic and extrahepatic vasculature are highly complex. Sinusoidal capillarization and endothelial dysfunction contribute to increased intrahepatic vascular resistance. Hemodynamic changes in the extrahepatic circulation, including splanchnic vasodilation and hyperdynamic circulation, play a significant role in the development of portal hypertension. Additionally, therapeutic strategies targeting these vascular mechanisms are diverse, including improvement of sinusoidal microcirculation, therapies targeting hepatic stellate cells activation, and pharmacological modulation of systemic vascular tone. Therefore, in this review, we will discuss the vascular-related mechanisms and treatment progress of portal hypertension in cirrhosis to provide a new theoretical basis and practical guidance for clinical treatment.<\/jats:p>","DOI":"10.3389\/fmed.2025.1515400","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:43:19Z","timestamp":1738305799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension"],"prefix":"10.3389","volume":"12","author":[{"given":"Yanqiu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1002\/mco2.721","article-title":"Liver cirrhosis: molecular mechanisms and therapeutic interventions","volume":"5","author":"Dong","year":"2024","journal-title":"MedComm (2020)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","author":"Guix\u00e9-Muntet","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.3390\/ijms25147873","article-title":"Liver fibrosis: from basic science towards clinical Progress, focusing on the central role of hepatic stellate cells","volume":"25","author":"Akk\u0131z","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2024.05.014","article-title":"Angiocrine signaling in sinusoidal homeostasis and liver diseases","volume":"81","author":"Gao","year":"2024","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3350\/cmh.2024.0022","article-title":"Liver sinusoidal endothelial cell: an important yet often overlooked player in the liver fibrosis","volume":"30","author":"Qu","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1749-6632.2002.tb04074.x","article-title":"Nitric oxide in liver diseases: friend, foe, or just passerby?","volume":"962","author":"Hon","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/liv.14366","article-title":"What's new in portal hypertension?","volume":"40","author":"Mauro","year":"2020","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/liv.14070","article-title":"Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis","volume":"39","author":"Lehmann","year":"2019","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"114396","DOI":"10.1016\/j.biopha.2023.114396","article-title":"Sulodexide attenuates liver fibrosis in mice by restoration of differentiated liver sinusoidal endothelial cell","volume":"160","author":"Huang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"eadk8446","DOI":"10.1126\/scitranslmed.adk8446","article-title":"Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose","volume":"16","author":"Tung","year":"2024","journal-title":"Sci Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bioactmat.2024.05.034","article-title":"Engineered SPIONs functionalized with endothelin a receptor antagonist ameliorate liver fibrosis by inhibiting hepatic stellate cell activation","volume":"39","author":"Ten Hove","year":"2024","journal-title":"Bioact Mater"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"155916","DOI":"10.1016\/j.phymed.2024.155916","article-title":"Jiawei Taohe Chengqi decoction attenuates CCl4 induced hepatic fibrosis by inhibiting HSCs activation via TGF-\u03b21\/CUGBP1 and IFN-\u03b3\/Smad 7 pathway","volume":"133","author":"Ye","year":"2024","journal-title":"Phytomedicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0491","DOI":"10.1097\/HC9.0000000000000491","article-title":"Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context","volume":"8","author":"Guillot","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"110357","DOI":"10.1016\/j.intimp.2023.110357","article-title":"Macrophage in liver fibrosis: identities and mechanisms","volume":"120","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1232070","DOI":"10.3389\/fimmu.2024.1232070","article-title":"Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells","volume":"15","author":"Sauer","year":"2024","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbrc.2015.12.093","article-title":"IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS\/p 38 signal pathway","volume":"470","author":"Pu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"116143","DOI":"10.1016\/j.biopha.2024.116143","article-title":"Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats","volume":"171","author":"Perram\u00f3n","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.7150\/ijbs.90781","article-title":"TXNIP in liver sinusoidal endothelial cells ameliorates alcohol-associated liver disease via nitric oxide production","volume":"20","author":"Jung","year":"2024","journal-title":"Int J Biol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jhep.2023.06.017","article-title":"5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial","volume":"79","author":"Vukotic","year":"2023","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0168-8278(99)80105-6","article-title":"Prolonged bleeding time in experimental cirrhosis: role of nitric oxide","volume":"30","author":"Albornoz","year":"1999","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/a-2190-8705","article-title":"Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis","volume":"124","author":"Ding","year":"2023","journal-title":"Thromb Haemost"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"BSR20240528","DOI":"10.1042\/BSR20240528","article-title":"Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein","volume":"44","author":"Owen","year":"2024","journal-title":"Biosci Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jcmgh.2023.06.005","article-title":"Endothelin receptor-A inhibition decreases Ductular reaction, liver fibrosis, and angiogenesis in a model of cholangitis","volume":"16","author":"Owen","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"112059","DOI":"10.1016\/j.celrep.2023.112059","article-title":"Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1","volume":"42","author":"Ortiz","year":"2023","journal-title":"Cell Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7932046","DOI":"10.1155\/2019\/7932046","article-title":"Carvedilol inhibits angiotensin II-induced proliferation and contraction in hepatic stellate cells through the rho A\/rho-kinase pathway","volume":"2019","author":"Wu","year":"2019","journal-title":"Biomed Res Int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2018.12.039","article-title":"The antifibrotic potential of a sustained release formulation of a PDGF\u03b2-receptor targeted rho kinase inhibitor","volume":"296","author":"van Dijk","year":"2019","journal-title":"J Control Release"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3748\/wjg.v24.i7.819","article-title":"Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase","volume":"24","author":"Li","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12964-019-0324-8","article-title":"Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells","volume":"17","author":"Wang","year":"2019","journal-title":"Cell Commun Signal"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/smll.201402870","article-title":"The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension","volume":"11","author":"Duong","year":"2015","journal-title":"Small"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0168-8278(00)00031-3","article-title":"Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure","volume":"34","author":"Ti\u00e8che","year":"2001","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fphar.2020.00009","article-title":"Endothelin-1\/nitric oxide ratio as a predictive factor of response to therapy with Terlipressin and albumin in patients with Type-1 Hepatorenal syndrome","volume":"11","author":"Abdel-Razik","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1042\/CS20160470","article-title":"Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats","volume":"131","author":"Tung","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.prostaglandins.2015.05.008","article-title":"Arachidonic acid metabolites and endothelial dysfunction of portal hypertension","volume":"120","author":"Sacerdoti","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"G953","DOI":"10.1152\/ajpgi.00013.2008","article-title":"Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension","volume":"295","author":"Skill","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1582-4934.2012.01563.x","article-title":"Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats","volume":"16","author":"Rosado","year":"2012","journal-title":"J Cell Mol Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"761517","DOI":"10.3389\/fmed.2021.761517","article-title":"COX-2\/sEH dual inhibitor PTUPB alleviates CCl 4-induced liver fibrosis and portal hypertension","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/metabo12050411","article-title":"Renin-angiotensin system in liver metabolism: gender differences and role of incretins","volume":"12","author":"Mastoor","year":"2022","journal-title":"Meta"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/CS20120030","article-title":"Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options","volume":"123","author":"Grace","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/ijmm_00000407","article-title":"Down-regulation of angiotensin II by sh RNA reduces collagen synthesis in hepatic stellate cells","volume":"25","author":"Yu","year":"2010","journal-title":"Int J Mol Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/term.2940","article-title":"Targeting Ang II\/AT1R signaling pathway by perindopril inhibits ongoing liver fibrosis in rat","volume":"13","author":"Abd El-Rahman","year":"2019","journal-title":"J Tissue Eng Regen Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41598-020-78946-3","article-title":"B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure","volume":"11","author":"Araujo","year":"2021","journal-title":"Sci Rep"},{"key":"ref45","first-page":"1901","article-title":"Plasma adrenomedullin levels in patients with hepatic cirrhosis","volume":"92","author":"F\u00e1brega","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/biom10101433","article-title":"cAMP signaling in pathobiology of alcohol associated liver disease","volume":"10","author":"Elnagdy","year":"2020","journal-title":"Biomol Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.kint.2017.02.017","article-title":"B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease","volume":"92","author":"Holditch","year":"2017","journal-title":"Kidney Int"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"BSR20240354","DOI":"10.1042\/BSR20240354","article-title":"Low-dose alcohol exacerbates hyperdynamic circulation and shunting in non-alcoholic cirrhotic rats","volume":"44","author":"Pun","year":"2024","journal-title":"Biosci Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl230072","article-title":"Recent advances in the pathogenesis and clinical evaluation of portal hypertension in chronic liver disease","volume":"18","author":"Kotani","year":"2024","journal-title":"Gut Liver"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/liv.15166","article-title":"Non-selective beta-blockers in patients with ascites: the complex interplay among the liver, kidney and heart","volume":"42","author":"T\u00e9llez","year":"2022","journal-title":"Liver Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.3390\/ijms25115807","article-title":"The renin-angiotensin system in liver disease","volume":"25","author":"McGrath","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/diagnostics14131372","article-title":"Clinical implications and Management of Spontaneous Portosystemic Shunts in liver cirrhosis","volume":"14","author":"Juncu","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1053\/j.gastro.2018.01.028","article-title":"Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis","volume":"154","author":"Sim\u00f3n-Talero","year":"2018","journal-title":"Gastroenterology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"100251","DOI":"10.1016\/j.jhepr.2021.100251","article-title":"New insights on the role of vascular endothelial growth factor in biliary pathophysiology","volume":"3","author":"Mariotti","year":"2021","journal-title":"JHEP Rep"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5604\/16652681.1198799","article-title":"Angiogenesis and portal-systemic collaterals in portal hypertension","volume":"15","author":"Gana","year":"2016","journal-title":"Ann Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"176278","DOI":"10.1016\/j.ejphar.2023.176278","article-title":"Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats","volume":"964","author":"Fan","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e12762","DOI":"10.1111\/cpr.12762","article-title":"Curcumol attenuates liver sinusoidal endothelial cell angiogenesis via regulating Glis-PROX1-HIF-1\u03b1 in liver fibrosis","volume":"53","author":"Yang","year":"2020","journal-title":"Cell Prolif"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"118819","DOI":"10.1016\/j.lfs.2020.118819","article-title":"micro RNA-322\/424 promotes liver fibrosis by regulating angiogenesis through targeting CUL2\/HIF-1\u03b1 pathway","volume":"266","author":"Wang","year":"2021","journal-title":"Life Sci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.21037\/qims-20-1328","article-title":"Collaterals in portal hypertension: anatomy and clinical relevance","volume":"11","author":"Maruyama","year":"2021","journal-title":"Quant Imaging Med Surg"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"176833","DOI":"10.1016\/j.ejphar.2024.176833","article-title":"Imperatorin attenuates CCl4-induced cirrhosis and portal hypertension by improving vascular remodeling and profibrogenic pathways","volume":"980","author":"Zhao","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"9466","DOI":"10.3748\/wjg.v21.i32.9466","article-title":"Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis","volume":"21","author":"Lluch","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/liv.12233","article-title":"Renal effects of NO-inhibition in patients with cirrhosis vs. healthy controls: a randomized placebo-controlled crossover study","volume":"34","author":"Bech","year":"2014","journal-title":"Liver Int"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/jgh.12119","article-title":"Basal release of nitric oxide in the mesenteric artery in portal hypertension and cirrhosis: role of dimethylarginine dimethylaminohydrolase","volume":"28","author":"Serna","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/liv.12101","article-title":"Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling","volume":"33","author":"Reiberger","year":"2013","journal-title":"Liver Int"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.gastro.2024.06.007","article-title":"Targeting 5-Hydroxytryptamine receptor 1A in the portal vein to decrease portal hypertension","volume":"167","author":"Zhu","year":"2024","journal-title":"Gastroenterology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"831311","DOI":"10.3389\/fphar.2022.831311","article-title":"Downregulation of Ca2+-activated cl-Channel TMEM16A mediated by angiotensin II in cirrhotic portal hypertensive mice","volume":"13","author":"Kondo","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e0050","DOI":"10.1097\/HC9.0000000000000050","article-title":"Heart rate variability is associated with disease severity and portal hypertension in cirrhosis","volume":"7","author":"Miceli","year":"2023","journal-title":"Hepatol Commun"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1002\/hep4.2102","article-title":"Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites","volume":"6","author":"Ripoll","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1038\/s41598-019-43513-y","article-title":"Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K\/AKT and cGMP signalling pathways","volume":"9","author":"Caracuel","year":"2019","journal-title":"Sci Rep"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/hep.1840400410","article-title":"Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis","volume":"40","author":"M\u00f8ller","year":"2004","journal-title":"Hepatology"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"934","DOI":"10.5009\/gnl240038","article-title":"Pharmacological interventions for cirrhotic ascites: from challenges to emerging therapeutic horizons","volume":"18","author":"Gao","year":"2024","journal-title":"Gut Liver"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J Hepatol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/liv.15896","article-title":"Cardiac dysfunction in patients with cirrhosis and acute decompensation","volume":"44","author":"Gananandan","year":"2024","journal-title":"Liver Int"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"100911","DOI":"10.1016\/j.jhepr.2023.100911","article-title":"Cardiomyopathy in cirrhosis: from pathophysiology to clinical care","volume":"6","author":"Liu","year":"2024","journal-title":"JHEP Rep"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3748\/wjg.v11.i6.846","article-title":"Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis","volume":"11","author":"Maksan","year":"2005","journal-title":"World J Gastroenterol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","article-title":"Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease","volume":"30","author":"Rocho\u0144","year":"2024","journal-title":"World J Gastroenterol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3390\/diagnostics14151606","article-title":"Alterations in intestinal mucosal barrier visualized by confocal laser Endomicroscopy in liver cirrhosis: A pilot trial (AMBIC)","volume":"14","author":"Rusticeanu","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1342356","DOI":"10.3389\/fmicb.2024.1342356","article-title":"Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001-2023)","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Microbiol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/apt.17727","article-title":"Association between gut-derived endotoxins and Porto-sinusoidal vascular disorder with portal hypertension","volume":"58","author":"Gioia","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/he.2000.6596","article-title":"Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis","volume":"31","author":"Nagasue","year":"2000","journal-title":"Hepatology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jhep.2013.01.038","article-title":"Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function","volume":"58","author":"Du Plessis","year":"2013","journal-title":"J Hepatol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5604\/16652681.1198816","article-title":"Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?","volume":"15","author":"Pijls","year":"2016","journal-title":"Ann Hepatol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2008.12.001","article-title":"Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome","volume":"136","author":"Zhang","year":"2009","journal-title":"Gastroenterology"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.arbres.2022.12.007","article-title":"Hepatopulmonary syndrome: A forgotten liver-induced lung vascular disorder","volume":"59","author":"Rodr\u00edguez-Roisin","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/HEP.0000000000000577","article-title":"Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites","volume":"79","author":"Chin","year":"2024","journal-title":"Hepatology"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.cmet.2024.07.003","article-title":"Hepatic BMAL1 and HIF1\u03b1 regulate a time-dependent hypoxic response and prevent hepatopulmonary-like syndrome","volume":"36","author":"Dandavate","year":"2024","journal-title":"Cell Metab"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"106987","DOI":"10.1016\/j.rmed.2022.106987","article-title":"Pulmonary vascular disease and exercise hemodynamics in chronic liver disease","volume":"202","author":"Douschan","year":"2022","journal-title":"Respir Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"111263","DOI":"10.1016\/j.biopha.2021.111263","article-title":"Tea polyphenols and levofloxacin alleviate the lung injury of hepatopulmonary syndrome in common bile duct ligation rats through endotoxin-TNF signaling","volume":"137","author":"Zhu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"100527","DOI":"10.1016\/j.jhepr.2022.100527","article-title":"Hepatopulmonary syndrome","volume":"4","author":"Raevens","year":"2022","journal-title":"JHEP Rep"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"120112","DOI":"10.1016\/j.lfs.2021.120112","article-title":"Combined exercise training improved exercise capacity and lung inflammation in rats with hepatopulmonary syndrome","volume":"287","author":"Nascimento","year":"2021","journal-title":"Life Sci"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"113254","DOI":"10.1016\/j.intimp.2024.113254","article-title":"Hepatoprotective effects of vildagliptin mitigates lung biochemical and histopathological changes in experimental hepatopulmonary syndrome model in rat","volume":"143","author":"Mangoura","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"000","DOI":"10.14218\/JCTH.2022.00421","article-title":"Serum soluble vascular endothelial growth factor receptor 1 as a potential biomarker of Hepatopulmonary syndrome","author":"Li","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jhep.2014.04.025","article-title":"Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis","volume":"61","author":"Horvatits","year":"2014","journal-title":"J Hepatol"},{"key":"ref96","first-page":"355","article-title":"Progress in investigating the pathogenesis of hepatopulmonary syndrome","volume":"9","author":"Zhang","year":"2010","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001218","article-title":"Unmet needs in diagnosis and management of portopulmonary hypertension: how far have we reached?","author":"Krowka","year":"2024","journal-title":"Hepatology"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/FJC.0000000000000650","article-title":"Roles of endothelin B receptors and endothelial nitric oxide synthase in the regulation of pulmonary hemodynamic in cirrhotic rats","volume":"73","author":"Khoramzadeh","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1164\/rccm.201807-1236OC","article-title":"Bone morphogenetic protein 9 is a mechanistic biomarker of Portopulmonary hypertension","volume":"199","author":"Nikolic","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"115740","DOI":"10.1016\/j.bcp.2023.115740","article-title":"Targeting collagen homeostasis for the treatment of liver fibrosis: opportunities and challenges","volume":"215","author":"Luangmonkong","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"16897","DOI":"10.1038\/s41598-024-67926-6","article-title":"Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo","volume":"14","author":"Geervliet","year":"2024","journal-title":"Sci Rep"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"114472","DOI":"10.1016\/j.biopha.2023.114472","article-title":"Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis","volume":"161","author":"Shan","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"111768","DOI":"10.1016\/j.jep.2019.01.045","article-title":"Raw and vinegar processed Curcuma wenyujin regulates hepatic fibrosis via bloking TGF-\u03b2\/Smad signaling pathways and up-regulation of MMP-2\/TIMP-1 ratio","volume":"246","author":"Xie","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.intimp.2019.03.060","article-title":"Influence of inflammasome pathway activation in macrophages on the matrix metalloproteinase expression of human hepatic stellate cells","volume":"72","author":"Robert","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.hbpd.2018.08.008","article-title":"Insulin-like growth factor binding protein related protein 1 knockdown attenuates hepatic fibrosis via the regulation of MMPs\/TIMPs in mice","volume":"18","author":"Ren","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.3390\/nu14183791","article-title":"Combination treatment with Hydroxytyrosol and vitamin E improves NAFLD-related fibrosis","volume":"14","author":"Panera","year":"2022","journal-title":"Nutrients"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"174201","DOI":"10.1016\/j.ejphar.2021.174201","article-title":"Alpha lipoic acid priming enhances the hepatoprotective effect of adipose derived stem cells in CCl4 induced hepatic injury in-vitro","volume":"906","author":"Yaqub","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"155878","DOI":"10.1016\/j.phymed.2024.155878","article-title":"Glycyrrhizic acid ameliorates hepatic fibrosis by inhibiting oxidative stress via AKR7A2","volume":"133","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"118646","DOI":"10.1016\/j.jep.2024.118646","article-title":"Specnuezhenide ameliorates hepatic fibrosis via regulating SIRT6-mediated inflammatory signaling cascades","volume":"335","author":"Qin","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"117206","DOI":"10.1016\/j.biopha.2024.117206","article-title":"Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation","volume":"178","author":"Benedicto","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"176629","DOI":"10.1016\/j.ejphar.2024.176629","article-title":"Arctigenin induces activated HSCs quiescence via AMPK-PPAR\u03b3 pathway to ameliorate liver fibrosis in mice","volume":"974","author":"Lv","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"113875","DOI":"10.1016\/j.celrep.2024.113875","article-title":"Hepatic Snai 1 and Snai 2 promote liver regeneration and suppress liver fibrosis in mice","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"110456","DOI":"10.1016\/j.intimp.2023.110456","article-title":"Human umbilical cord-derived mesenchymal stromal cells alleviate liver cirrhosis through the hippo\/YAP\/Id1 pathway and macrophage-dependent mechanism","volume":"123","author":"Yao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"108563","DOI":"10.1016\/j.pharmthera.2023.108563","article-title":"Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: current perspectives and future challenges","volume":"253","author":"Yadav","year":"2024","journal-title":"Pharmacol Ther"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"e0530","DOI":"10.1097\/HC9.0000000000000530","article-title":"Statins for the prevention of cirrhosis complications: an American emulation of the stat liver trial","volume":"8","author":"Tapper","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.3390\/pharmaceutics15102463","article-title":"Optimization of statin-loaded delivery nanoparticles for treating chronic liver diseases by targeting liver sinusoidal endothelial cells","volume":"15","author":"Gil","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"e0456","DOI":"10.1097\/HC9.0000000000000456","article-title":"Statin the course: navigating unchartered territory in cirrhosis","volume":"8","author":"Kezer","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1454829","DOI":"10.3389\/fphar.2024.1454829","article-title":"STA-9090 in combination with a statin exerts enhanced protective effects in rats fed a high-fat diet and exposed to diethylnitrosamine and thioacetamide","volume":"15","author":"Abdelhamid","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/hep4.1881","article-title":"Treatment with simvastatin and Rifaximin restores the plasma Metabolomic profile in patients with decompensated cirrhosis","volume":"6","author":"Pose","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"e0332","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol Commun"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3748\/wjg.v27.i28.4639","article-title":"Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy","volume":"27","author":"Mu\u00f1oz","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03880.x","article-title":"Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy","volume":"29","author":"Villanueva","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ajg.2009.661","article-title":"NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study","volume":"105","author":"Berzigotti","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/08923973.2020.1830104","article-title":"Nicorandil and atorvastatin attenuate carbon tetrachloride \u2013 induced liver fibrosis in rats","volume":"42","author":"Abdel-Sattar","year":"2020","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/liv.14757","article-title":"Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study","volume":"41","author":"Zipprich","year":"2021","journal-title":"Liver Int"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/bph.15289","article-title":"Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt\/\u03b2-catenin signalling via interaction with Gli 1","volume":"178","author":"Zhang","year":"2021","journal-title":"Br J Pharmacol"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"151427","DOI":"10.1016\/j.ejcb.2024.151427","article-title":"The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension","volume":"103","author":"Zhang","year":"2024","journal-title":"Eur J Cell Biol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jconrel.2024.02.022","article-title":"Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis","volume":"368","author":"Wang","year":"2024","journal-title":"J Control Release"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"e2311474","DOI":"10.1002\/adma.202311474","article-title":"Vicious cycle-breaking lipid nanoparticles remodeling multicellular crosstalk to reverse liver fibrosis","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv Mater"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3748\/wjg.v30.i32.3766","article-title":"Mesenchymal stem cell therapy for liver fibrosis need \"partner\": results based on a meta-analysis of preclinical studies","volume":"30","author":"Xu","year":"2024","journal-title":"World J Gastroenterol"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"20035","DOI":"10.1038\/s41598-024-70281-1","article-title":"Comprehensive evaluation of the mechanism of human adipose mesenchymal stem cells ameliorating liver fibrosis by transcriptomics and metabolomics analysis","volume":"14","author":"Ji","year":"2024","journal-title":"Sci Rep"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/liv.14674","article-title":"Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD \u2265 12 over 5 years of follow-up","volume":"41","author":"Cal\u00e8s","year":"2021","journal-title":"Liver Int"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s12072-024-10687-1","article-title":"Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial","volume":"18","author":"Ranjan","year":"2024","journal-title":"Hepatol Int"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/apt.17824","article-title":"Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data","volume":"59","author":"Villanueva","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jhep.2023.10.007","article-title":"Predicting survival in patients with \u201cnon-high-risk\u201d acute variceal bleeding receiving \u03b2-blockers+ligation to prevent re-bleeding","volume":"80","author":"Balcar","year":"2024","journal-title":"J Hepatol"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/apt.17380","article-title":"Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis","volume":"57","author":"Gillespie","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/HEP.0000000000000820","article-title":"Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study","volume":"80","author":"Terbah","year":"2024","journal-title":"Hepatology"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.010","article-title":"Long-term continuous Terlipressin infusion improves cardiac Reserve in Patients with Decompensated Cirrhosis","author":"Terbah","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/s41598-024-56873-x","article-title":"Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding","volume":"14","author":"Rehman","year":"2024","journal-title":"Sci Rep"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.gastro.2023.10.016","article-title":"AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review","volume":"166","author":"Garcia-Tsao","year":"2024","journal-title":"Gastroenterology"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"155830","DOI":"10.1016\/j.phymed.2024.155830","article-title":"Hydroxysafflor yellow A exerts anti-fibrotic and anti-angiogenic effects through mi R-29a-3p\/PDGFRB axis in liver fibrosis","volume":"132","author":"Xue","year":"2024","journal-title":"Phytomedicine"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"e14287","DOI":"10.1111\/eci.14287","article-title":"Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension","volume":"54","author":"Pun","year":"2024","journal-title":"Eur J Clin Investig"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/cells13060538","article-title":"Tofogliflozin delays portal hypertension and hepatic fibrosis by inhibiting sinusoidal Capillarization in cirrhotic rats","volume":"13","author":"Asada","year":"2024","journal-title":"Cells"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"176010","DOI":"10.1016\/j.ejphar.2023.176010","article-title":"Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF","volume":"958","author":"Vairappan","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"10389","DOI":"10.1111\/jcmm.16968","article-title":"Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress","volume":"25","author":"Tai","year":"2021","journal-title":"J Cell Mol Med"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"176066","DOI":"10.1016\/j.ejphar.2023.176066","article-title":"Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: emphasis on gal-1\/NRP-1\/TGF-\u03b2 and gal-1\/NRP-1\/VEGFR2 pathways","volume":"959","author":"Noah","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"174713","DOI":"10.1016\/j.ejphar.2021.174713","article-title":"Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction","volume":"915","author":"Zheng","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"101379","DOI":"10.1016\/j.jcmgh.2024.101379","article-title":"Microbial-derived Urolithin A targets GLS1 to inhibit Glutaminolysis and attenuate cirrhotic portal hypertension","volume":"18","author":"Li","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/hep4.1987","article-title":"Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic rats","volume":"6","author":"Gunarathne","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"119895","DOI":"10.1016\/j.lfs.2021.119895","article-title":"DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility","volume":"284","author":"Wang","year":"2021","journal-title":"Life Sci"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.3390\/ijms22147662","article-title":"Glycyrrhizin attenuates portal hypertension and collateral shunting via inhibition of extrahepatic angiogenesis in cirrhotic rats","volume":"22","author":"Pun","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J Hepatol"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/2050640620944140","article-title":"Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats","volume":"8","author":"Brusilovskaya","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1042\/CS20200452","article-title":"Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2\u03b1-activated COX-TXA2 pathway","volume":"134","author":"Tsai","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00109-019-01746-4","article-title":"AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model","volume":"97","author":"Hu","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"116068","DOI":"10.1016\/j.biopha.2023.116068","article-title":"Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist","volume":"171","author":"Castillo","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1124\/jpet.122.001532","article-title":"Soluble guanylyl cyclase activator BI 685509 reduces portal hypertension and portosystemic shunting in a rat Thioacetamide-induced cirrhosis model","volume":"386","author":"Jones","year":"2023","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1515400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:43:24Z","timestamp":1738305804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1515400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":158,"alternative-id":["10.3389\/fmed.2025.1515400"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1515400","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"1515400"}}